Summary

Market Size & Trends

The U.S. cell culture media & cell lines market size was valued at USD 1.97 billion in 2024 and is anticipated to reach USD 4.36 billion by 2033, growing at a CAGR of 9.45% from 2025 to 2033. This growth is driven by increasing demand for biopharmaceutical production, advancements in regenerative medicine, and rising investments in research and development activities. Moreover, the expanding application of cell culture technologies in drug discovery and personalized medicine will fuel market expansion further over the forecast period.

U.S. Cell Culture Media And Cell Lines Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For
this study, Grand View Research has segmented the U.S. cell culture media & cell lines market report on the basis of product, application, and end use.
• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Traditional Cell Lines
• Classical Media
• Stem Cells & Blood-derived Cells
• Specialty Media Products
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Biopharmaceutical Production
• Diagnostics
• Drug Screening and Development
• Tissue Engineering and Regenerative Medicine
• Other Applications
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Large Biopharmaceutical Companies
• Small and Mid-sized Biotechnology Companies
• Contract Research and Manufacturing Organizations (CROs/CMOs)
• Research and Academic Institutes
• Hospitals and Diagnostic Laboratories
• Other End Uses

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.2.1. Product Segment
1.2.2. Application Segment
1.2.3. End Use Segment
1.3. Information analysis
1.4. Market formulation & data visualization
1.5. Data validation & publishing
1.6. Information Procurement
1.6.1. Primary Research
1.7. Information or Data Analysis
1.8. Market Formulation & Validation
1.9. Market Model
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Insights Landscape
Chapter 3. U.S. Cell Culture Media & Cell Lines Market Variables & Trends
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook.
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Advancements in Regenerative Medicine
3.2.1.2. Advancements in Technology and Data Analytics
3.2.2. Market restraint analysis
3.2.2.1. High Cost of Specialized Media and Cell Lines
3.2.2.2. Stringent Regulatory and Quality Requirements
3.3. U.S. Cell Culture Media & Cell Lines Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.2. PESTEL Analysis
Chapter 4. U.S. Cell Culture Media & Cell Lines Market: Product Estimates & Trend Analysis
4.1. Product Segment Dashboard
4.2. U.S. Cell Culture Media & Cell Lines Market Product Movement Analysis
4.3. U.S. Cell Culture Media & Cell Lines Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
4.4. Traditional Cell Lines
4.4.1. Traditional Cell Lines Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
4.5. Classical Media
4.5.1. Classical Media Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
4.6. Stem Cells & Blood-derived Cells
4.6.1. Stem Cells & Blood-derived Cells Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
4.7. Specialty Media Products
4.7.1. Specialty Media Products Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
Chapter 5. U.S. Cell Culture Media & Cell Lines Market: Application Estimates & Trend Analysis
5.1. Application Segment Dashboard
5.2. U.S. Cell Culture Media & Cell Lines Market Application Movement Analysis
5.3. U.S. Cell Culture Media & Cell Lines Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
5.4. Biopharmaceutical Production
5.4.1. Biopharmaceutical Production market estimates and forecasts 2021 to 2033 (USD Million)
5.5. Diagnostics
5.5.1. Diagnostics market estimates and forecasts 2021 to 2033 (USD Million)
5.6. Drug Screening and Development
5.6.1. Drug Screening and Development market estimates and forecasts 2021 to 2033 (USD Million)
5.7. Tissue Engineering and Regenerative Medicine
5.7.1. Tissue Engineering and Regenerative Medicine market estimates and forecasts 2021 to 2033 (USD Million)
5.8. Other Applications
5.8.1. Other Applications market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 6. U.S. Cell Culture Media & Cell Lines Market: End use Estimates & Trend Analysis
6.1. End use Segment Dashboard
6.2. U.S. Cell Culture Media & Cell Lines Market End use Movement Analysis
6.3. U.S. Cell Culture Media & Cell Lines Market Size & Trend Analysis, by End use, 2021 to 2033 (USD Million)
6.4. Large Biopharmaceutical Companies
6.4.1. Large Biopharmaceutical Companies market estimates and forecasts 2021 to 2033 (USD Million)
6.5. Small and Mid-sized Biotechnology Companies
6.5.1. Small and Mid-sized Biotechnology Companies market estimates and forecasts 2021 to 2033 (USD Million)
6.6. Contract Research and Manufacturing Organizations (CROs/CMOs)
6.6.1. Contract Research and Manufacturing Organizations (CROs/CMOs) market estimates and forecasts 2021 to 2033 (USD Million)
6.7. Research and Academic Institutes
6.7.1. Research and Academic Institutes market estimates and forecasts 2021 to 2033 (USD Million)
6.8. Hospitals and Diagnostic Laboratories
6.8.1. Hospitals and Diagnostic Laboratories market estimates and forecasts 2021 to 2033 (USD Million)
6.9. Other End Uses
6.9.1. Other End Uses market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 7. Competitive Landscape
7.1. Company/Competition Categorization
7.2. Strategy Mapping
7.3. Company Market Position Analysis, 2024
7.4. Company Profiles/Listing
7.4.1. Sartorius AG
7.4.1.1. Company overview
7.4.1.2. Financial performance
7.4.1.3. Product benchmarking
7.4.1.4. Strategic initiatives
7.4.2. Danaher
7.4.2.1. Company overview
7.4.2.2. Financial performance
7.4.2.3. Product benchmarking
7.4.2.4. Strategic initiatives
7.4.3. Merck KGaA
7.4.3.1. Company overview
7.4.3.2. Financial performance
7.4.3.3. Product benchmarking
7.4.3.4. Strategic initiatives
7.4.4. Thermo Fisher Scientific, Inc.
7.4.4.1. Company overview
7.4.4.2. Financial performance
7.4.4.3. Product benchmarking
7.4.4.4. Strategic initiatives
7.4.5. FUJIFILM Corporation
7.4.5.1. Company overview
7.4.5.2. Financial performance
7.4.5.3. Product benchmarking
7.4.5.4. Strategic initiatives
7.4.6. Lonza
7.4.6.1. Company overview
7.4.6.2. Financial performance
7.4.6.3. Product benchmarking
7.4.6.4. Strategic initiatives
7.4.7. STEMCELL Technologies
7.4.7.1. Company overview
7.4.7.2. Product benchmarking
7.4.7.3. Strategic initiatives
7.4.8. PromoCell GmbH
7.4.8.1. Company overview
7.4.8.2. Product benchmarking
7.4.8.3. Strategic initiatives
7.4.9. ATCC
7.4.9.1. Company overview
7.4.9.2. Product benchmarking
7.4.9.3. Strategic initiatives
7.4.10. AllCells.
7.4.10.1. Company overview
7.4.10.2. Product benchmarking
7.4.10.3. Strategic initiatives